Tango Therapeutics TNGX Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept tngx:AccruedExpensesAndOtherCurrentLiabilities.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's accrued expenses and other current liabilities?
- Tango Therapeutics (TNGX) reported accrued expenses and other current liabilities of $9.07M in Q1 2026.
- How has Tango Therapeutics's accrued expenses and other current liabilities changed year-over-year?
- Tango Therapeutics's accrued expenses and other current liabilities decreased by 12.6% year-over-year, from $10.37M to $9.07M.
- What is the long-term trend for Tango Therapeutics's accrued expenses and other current liabilities?
- Over 5 years (2020 to 2025), Tango Therapeutics's accrued expenses and other current liabilities has grown at a 23.7% compound annual growth rate (CAGR), from $6.14M to $17.76M.
- What does accrued expenses and other current liabilities mean?
- This represents the aggregate of short-term obligations that have been incurred but not yet invoiced or paid by the end of the reporting period. In a biotechnology context, this typically includes accrued research and development costs, clinical trial expenses, and professional service fees. Monitoring this balance helps investors assess the company's near-term cash outflow requirements and the accuracy of its expense recognition relative to operational milestones.